摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-溴苯磺酰胺 | 132367-80-7

中文名称
N-溴苯磺酰胺
中文别名
——
英文名称
N-bromobenzenesulphonamide
英文别名
N-Brom-benzolsulfonsaeure-amid;N-Bromobenzenesulfonylamide;N-bromobenzene sulfonamide;N-bromobenzenesulfonamide
N-溴苯磺酰胺化学式
CAS
132367-80-7
化学式
C6H6BrNO2S
mdl
——
分子量
236.089
InChiKey
CIZZBNHBFCGHME-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    54.6
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    N-溴苯磺酰胺hydroxide 作用下, 生成 bromamine B
    参考文献:
    名称:
    Puttaswamy; Vaz, Nirmala, Journal of the Indian Chemical Society, 2004, vol. 81, # 6, p. 479 - 483
    摘要:
    DOI:
  • 作为产物:
    描述:
    bromamine B 作用下, 生成 N-溴苯磺酰胺
    参考文献:
    名称:
    Puttaswamy; Vaz, Nirmala, Journal of the Indian Chemical Society, 2004, vol. 81, # 6, p. 479 - 483
    摘要:
    DOI:
  • 作为试剂:
    描述:
    D-甘露糖sodium hydroxideN-溴苯磺酰胺 、 sodium perchlorate 、 sodium 作用下, 以 为溶剂, 生成 D-甘露己醣酸
    参考文献:
    名称:
    Iyengar, T. Asha; Mahadevappa, D. S., Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical and Analytical, 1992, vol. 31, # 11, p. 838 - 844
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS
    申请人:University College Dublin, National University of Ireland, Dublin
    公开号:US20160102051A1
    公开(公告)日:2016-04-14
    The invention generally relates to methods and compounds for treating proliferative disorders, viral infections, or both. In some embodiments, the invention provides an anticancer or antiviral compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating a proliferative disorder or a viral infection including administering an anticancer or antiviral compound that binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.
    这项发明通常涉及用于治疗增殖性疾病、病毒感染或两者的方法和化合物。在某些实施例中,该发明提供了一种抗癌或抗病毒化合物,包括一种取代硝基苯氧基苯基、磺酰脲和烷基。在某些实施例中,该发明提供了一种治疗增殖性疾病或病毒感染的方法,包括给予一种结合到血栓素A2受体、对TPalpha(TPα)或TPbeta(TPβ)受体亚型具有优先结合的抗癌或抗病毒化合物。
  • CHEMICAL COMPOUNDS
    申请人:Antabio SAS
    公开号:EP3431474A1
    公开(公告)日:2019-01-23
    The invention relates to a compound which is a thiazole derivative of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, Ⓐ, Z, L, X, m, n and p are as defined herein. The compounds are useful in the treatment and prevention of bacterial infection.
    这项发明涉及一种化合物,该化合物是式(I)的噻唑衍生物,或其药用可接受的盐, 其中R1、R2、R3、R4、R5、R6、R7、Ⓐ、Z、L、X、m、n和p的定义如本文所述。这些化合物在治疗和预防细菌感染方面是有用的。
  • Biaryl sulfonamides and methods for using same
    申请人:Levin Ian Jeremy
    公开号:US20050143422A1
    公开(公告)日:2005-06-30
    The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.
    本发明涉及联苯磺酰胺及其用途,例如作为金属蛋白酶抑制剂。
  • [EN] ARYL-PHENYL-SULFONAMIDO-CYCLOALKYL COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS ARYL-PHÉNYL-SULFONAMINO-CYCLOALKYLE ET LEURS UTILISATIONS
    申请人:PIMCO 2664 LTD
    公开号:WO2010032009A1
    公开(公告)日:2010-03-25
    The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as "APSAC compounds"). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc. Formula (I).
    本发明一般涉及治疗化合物领域,更具体地涉及以下化学式的某些芳基-苯基-磺酰胺基-环烷基化合物(以下统称为“APSAC化合物”)。本发明还涉及包含这种化合物的药物组合物,以及这种化合物和组合物的使用,无论是在体外还是体内,用于治疗炎症和/或关节破坏和/或骨质流失等疾病,过度和/或不适当和/或持续激活免疫系统介导的疾病,例如炎症性和自身免疫性疾病,如类风湿关节炎、银屑病、银屑病性关节炎、慢性阻塞性肺病(COPD)、动脉粥样硬化、炎症性肠病、强直性脊柱炎等;与骨质流失相关的疾病,例如类风湿性关节炎中由过度破骨细胞活动引起的骨质流失、骨质疏松症、癌症相关的骨病、帕金森病等等;以及癌症,如血液恶性肿瘤、实体肿瘤等。化学式(I)。
  • [EN] ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS ARYL-PHÉNYL-SULFONAMINO-PHÉNYLÈNE ET LEURS UTILISATIONS
    申请人:PIMCO 2664 LTD
    公开号:WO2010032010A1
    公开(公告)日:2010-03-25
    The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as "APSAP compounds"). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc.
    本发明通常涉及治疗化合物领域,更具体地涉及以下式(I)的某些芳基苯磺酰胺基苯基化合物(以下统称为“APSAP化合物”)。本发明还涉及包含这些化合物的药物组合物,以及这些化合物和组合物在体内外的使用,例如用于治疗炎症和/或关节破坏和/或骨质流失;过度和/或不适当和/或持续激活免疫系统的疾病;炎症性和自身免疫性疾病,例如类风湿关节炎、牛皮癣、银屑病性关节炎、慢性阻塞性肺病(COPD)、动脉粥样硬化、炎症性肠病、强直性脊柱炎等;与骨质流失相关的疾病,例如类风湿性关节炎中与过度破骨细胞活性相关的骨质流失、骨质疏松症、癌症相关骨病、帕吉特病等;以及癌症,如血液系统恶性肿瘤、实体肿瘤等。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐